Kihara James's Form 4 filing
Acadia Pharmaceuticals Inc (ACAD) · filed Nov 19, 2024
- Accession no.
- 0001415889-24-027293
- Filed
- Nov 19, 2024
- Trade date
- Nov 17-19, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $68.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kihara JamesCIK 0001816160 | Officer (PRINCIPAL ACCOUNTING OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 17, 2024 | Common Stock | MOption exerciseAcquired | +3,965 | –F1 | – | 19,971 | Direct | |
| Nov 17, 2024 | Common Stock | MOption exerciseAcquired | +3,965 | –F1 | – | 23,936 | Direct | |
| Nov 19, 2024 | Common Stock | SSaleDisposed | −4,073 | $16.81F4 | −$68,467.13 | 19,863 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 17, 2024 | Common Stock | MOption exerciseDisposed | −3,965 | $0.00 | $0 | 3,966 | Direct | |
| Nov 17, 2024 | Common Stock | MOption exerciseDisposed | −3,965 | $0.00 | $0 | 3,966 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
Referenced by the price of 2 transactions in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.768 to $16.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Referenced by the price of 1 transaction in Table I.